Drug shortages have rocked the US, imperiling access to therapeutics for millions of patients with a wide array of diseases and conditions. A new Becker’s Hospital Review article lays out 7 of the most prominent drug shortages to watch. One is the attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamphetamine dimesylate).
According to Paige Twenter, “As of June 19, three capsules are in shortage and four are available from Takeda Pharmaceuticals. The medication is indicated for attention-deficit/hyperactivity disorder. A manufacturing delay caused 40 milligram capsules to be on back order until late June or early July, the drugmaker predicted, and 60 milligram and 70 milligram capsules are expected to be in shortage until September. The chewable tablets are not affected by this shortage, according to the ASHP.”
To read more, click here.
(Source: Becker’s Hospital Review, June 26th, 2023)